Works matching AU Kaiser, Martin

Results: 177
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Exposure‐Response and Population Pharmacokinetic Analyses of a Novel Subcutaneous Formulation of Daratumumab Administered to Multiple Myeloma Patients.

    Published in:
    Journal of Clinical Pharmacology, 2021, v. 61, n. 5, p. 614, doi. 10.1002/jcph.1771
    By:
    • Luo, Man (Melody);
    • Usmani, Saad Z.;
    • Mateos, Maria‐Victoria;
    • Nahi, Hareth;
    • Chari, Ajai;
    • San‐Miguel, Jesus;
    • Touzeau, Cyrille;
    • Suzuki, Kenshi;
    • Kaiser, Martin;
    • Carson, Robin;
    • Heuck, Christoph;
    • Qi, Ming;
    • Zhou, Honghui;
    • Sun, Yu‐Nien;
    • Parasrampuria, Dolly A.
    Publication type:
    Article
    12
    13
    14
    15

    The MUK eight protocol: a randomised phase II trial of cyclophosphamide and dexamethasone in combination with ixazomib, in relapsed or refractory multiple myeloma (RRMM) patients who have relapsed after treatment with thalidomide, lenalidomide and a proteasome inhibitor.

    Published in:
    2020
    By:
    • Hinsley, Samantha;
    • Walker, Katrina;
    • Sherratt, Debbie;
    • Bailey, Lucy;
    • Reed, Sadie;
    • Flanagan, Louise;
    • McKee, Sophie;
    • Brudenell Straw, Fiona;
    • Dawkins, Bryony;
    • Meads, David;
    • Auner, Holger W.;
    • Kaiser, Martin F.;
    • Cook, Mark;
    • Brown, Sarah;
    • Cook, Gordon;
    • Myeloma UK Clinical Trials Network
    Publication type:
    journal article
    16

    The CCND1 c.870G>A polymorphism is a risk factor for t(11;14)(q13;q32) multiple myeloma.

    Published in:
    Nature Genetics, 2013, v. 45, n. 5, p. 522, doi. 10.1038/ng.2583
    By:
    • Weinhold, Niels;
    • Johnson, David C;
    • Chubb, Daniel;
    • Chen, Bowang;
    • Försti, Asta;
    • Hosking, Fay J;
    • Broderick, Peter;
    • Ma, Yussanne P;
    • Dobbins, Sara E;
    • Hose, Dirk;
    • Walker, Brian A;
    • Davies, Faith E;
    • Kaiser, Martin F;
    • Li, Ni L;
    • Gregory, Walter A;
    • Jackson, Graham H;
    • Witzens-Harig, Mathias;
    • Neben, Kai;
    • Hoffmann, Per;
    • Nöthen, Markus M
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34
    35

    Immune responses to COVID‐19 booster vaccinations in intensively anti‐CD38 antibody treated patients with ultra‐high‐risk multiple myeloma: results from the Myeloma UK (MUK) nine OPTIMUM trial.

    Published in:
    British Journal of Haematology, 2023, v. 201, n. 5, p. 845, doi. 10.1111/bjh.18714
    By:
    • Faustini, Sian E.;
    • Hall, Andrew;
    • Brown, Sarah;
    • Roberts, Sadie;
    • Hill, Harriet;
    • Stamataki, Zania;
    • Jenner, Matthew W.;
    • Owen, Roger G.;
    • Pratt, Guy;
    • Cook, Gordon;
    • Richter, Alex;
    • Drayson, Mark T.;
    • Kaiser, Martin F.;
    • Heaney, Jennifer L. J.
    Publication type:
    Article
    36

    The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from 'Myeloma XI', a multicentre, open‐label, randomised, phase III trial.

    Published in:
    British Journal of Haematology, 2023, v. 201, n. 2, p. 267, doi. 10.1111/bjh.18600
    By:
    • Jenner, Matthew W.;
    • Pawlyn, Charlotte;
    • Davies, Faith E.;
    • Menzies, Tom;
    • Hockaday, Anna;
    • Olivier, Catherine;
    • Jones, John R.;
    • Karunanithi, Kamaraj;
    • Lindsay, Jindriska;
    • Kishore, Bhuvan;
    • Cook, Gordon;
    • Drayson, Mark T.;
    • Kaiser, Martin F.;
    • Owen, Roger G.;
    • Gregory, Walter;
    • Cairns, David A.;
    • Morgan, Gareth J.;
    • Jackson, Graham H.
    Publication type:
    Article
    37

    Early relapse after high‐dose melphalan autologous stem cell transplant predicts inferior survival and is associated with high disease burden and genetically high‐risk disease in multiple myeloma.

    Published in:
    British Journal of Haematology, 2021, v. 193, n. 3, p. 551, doi. 10.1111/bjh.16793
    By:
    • Bygrave, Ceri;
    • Pawlyn, Charlotte;
    • Davies, Faith;
    • Craig, Zoe;
    • Cairns, David;
    • Hockaday, Anna;
    • Jenner, Matthew;
    • Cook, Gordon;
    • Drayson, Mark;
    • Owen, Roger;
    • Gregory, Walter;
    • Morgan, Gareth;
    • Jackson, Graham;
    • Kaiser, Martin
    Publication type:
    Article
    38
    39
    40
    41
    42
    43

    Sanfte Festkörperchemie.

    Published in:
    Nachrichten aus der Chemie, 2013, v. 61, n. 1, p. 26, doi. 10.1002/nadc.201390006
    By:
    • Groh, Matthias F.;
    • Heise, Martin;
    • Kaiser, Martin;
    • Ruck, Michael
    Publication type:
    Article
    44
    45
    46
    47

    OAB-060: Prospective comparison of contemporary whole body MRI and FDG PET/CT for disease detection and correlation with markers of disease burden in myeloma: results of the iTIMM trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S37, doi. 10.1016/S2152-2650(21)02132-7
    By:
    • Kaiser, Martin;
    • Porta, Nuria;
    • sharma, Bhupinder;
    • Levine, Daniel;
    • Dow-Mu Koh;
    • Boyd, Kevin;
    • Pawlyn, Charlotte;
    • Ridell, Angela;
    • Downey, Katherine;
    • Croft, James;
    • Bonner, Alison;
    • Morgan, Veronica;
    • Stern, Simon;
    • Jones, Lydia;
    • Cheung, Betty;
    • Kyriakou, Charalampia;
    • Kaczmarek, Pawel;
    • Winfield, jessica;
    • Blackledge, Matthew;
    • Oyen, Wim
    Publication type:
    Article
    48

    OAB-015: Minimal residual disease following autologous stem cell transplant for myeloma patients in the Myeloma XI trial: prognostic significance and the impact of lenalidomide maintenance and molecular risk.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S10, doi. 10.1016/S2152-2650(21)02089-9
    By:
    • De Tute, Ruth;
    • Pawlyn, Charlotte;
    • Cairns, David;
    • Davies, Faith;
    • Rawstron, Andy;
    • Jones, John;
    • Hockaday, Anna;
    • Menzies, Tom;
    • Henderson, Rowena;
    • Cook, Gordon;
    • Drayson, Mark;
    • Jenner, Matthew;
    • Kaiser, Martin;
    • Gregory, Walter;
    • Morgan, Gareth;
    • Jackson, Graham;
    • Owen, Roger
    Publication type:
    Article
    49

    OAB-012: Depth of response and MRD in newly diagnosed ultra high-risk myeloma and plasma cell leukemia treated with Dara-CVRd and V-MEL ASCT: results of the molecularly stratified UK OPTIMUM/MUKnine trial.

    Published in:
    Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S8, doi. 10.1016/S2152-2650(21)02086-3
    By:
    • Kaiser, Martin;
    • Hall, Andrew;
    • Walker, Katrina;
    • Tute, Ruth De;
    • Roberts, Sadie;
    • Ingleson, Emma;
    • Bowles, Kristian;
    • Garg, Mamta;
    • Lokare, Anand;
    • Messiou, Christina;
    • Jackson, Graham;
    • Pratt, Guy;
    • Cook, Gordon;
    • Drayson, Mark;
    • Owen, Roger;
    • Brown, Sarah;
    • Jenner, Matthew
    Publication type:
    Article
    50